Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.88 - $107.37
Previous CloseN/A
Volume227.93K
Average Volume (3M)640.47K
Market Cap
$3.81B
Enterprise Value$3.99B
Total Cash (Recent Filing)$105.68M
Total Debt (Recent Filing)$54.08M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
May 08, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding54,944,010
10 Day Avg. Volume661,962
30 Day Avg. Volume640,472
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)35.30
Price to Cash Flow (P/CF)-20.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit36.93
Enterprise Value/Ebitda-40.23
Forecast
1Y Price Target
$117.15Price Target Upside68.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Arcellx Inc News
PremiumCompany Announcements
Arcellx Inc Announces Board Changes for Strategic Growth
PremiumCompany Announcements
Arcellx Reports Promising 2024 Financial and Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesStrong conviction exists that the outcomes related to movement neurotoxicity and progression-free survival for anito-cel will be positive, differentiating it from the market leader, Carvykti.
Financial HealthEnding with $626M in cash, equivalents, and marketable securities, the company reiterated a financial runway into 2027, indicating strong financial health.
Partnership AdvantagesArcellx's partnership with Kite Pharma is viewed as a significant advantage for commercialization due to Kite's substantial footprint in the cell therapy industry and established manufacturing capabilities.
Bears Say
Competitive LandscapeAnito-cel's efficacy data is viewed as comparable to Legend’s CARTITUDE-1 study of Carvykti, suggesting a competitive challenge.
Market CompetitionDespite positive prospects, anito-cel faces competition from existing market leaders like Carvykti, which could impact its market penetration.
---
Ownership Overview
3.06% Insiders
25.03% Mutual Funds
0.06% Other Institutional Investors
59.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $47.88 and its highest was $107.37 in the past 12 months.
What is Arcellx Inc’s market cap?
Arcellx Inc’s market cap is $3.81B.
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Feb 27, 2025. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.551 by -$0.319.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -0.76.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 54,944,010 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.551. Following the earnings report the stock price went up 5.587%.
Which hedge fund is a major shareholder of Arcellx Inc?
Currently, no hedge funds are holding shares in ACLX
---
Arcellx Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.15 (68.97% Upside)
$117.15 (68.97% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 520.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.76%
12-Months-Change
Fundamentals
Return on Equity
-22.84%
Trailing 12-Months
Asset Growth
-13.79%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
---
ACLX Stock 12 Month Forecast
Average Price Target
$117.15
▲(68.97% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Editas Medicine
―
Best Analysts Covering ACLX
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+51.87%
assigned a buy rating 5 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +51.87% per trade.
---